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  Atypical medullary carcinomas and carcinosarcoma 
have unique histopathological features.  Here we present 
a case with a breast malignancy that had pathological 
characteristics of both. A 54-year old patient with a malig-
nant breast mass received 6 cycles of adriamycin-based 
chemotherapy, followed by 3 cycles of paclitaxel mono-
therapy, and had a poor clinical response to treatment. A 
modified radical mastectomy was performed. The patho-
logical diagnosis was complicated by an inability to dis-
tinguish between atypical medullary carcinoma and 
carcinosarcoma. The findings included a tumor that was 
well-circumscribed, high grade and a syncytial growth
pattern as well as biphasic sarcomatous and carcinoma-
tous characteristics. In conclusion, atypical medullary car-
cinoma and carcinosarcoma of the breast have entirely dif-
ferent prognoses and should be managed differently. Both 
should be treated by surgical resection, and additional 
therapy should be considered based on the cancer with 
the poorer prognosis. (Cancer Res Treat. 2007;39:134- 
137)
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INTRODUCTION
Breast cancer is a heterogeneous disease with various 
histopathological types. Infiltrating ductal carcinoma (IDC) is 
the most common type, accounting for 80% of all breast 
cancers. While many studies have identified the clinical and 
histological features of IDC, much less is known about less 
common histological types of breast cancer such as carcino-
sarcoma, mucinous, tubular and medullary carcinomas. Among 
these cancers, medullary carcinoma accounts for 1 to 10 percent 
of invasive breast cancers (1,2); it is characterized by a 
well-circumscribed, high-grade tumor with a syncytial growth 
pattern   with aggressive infiltration of mononuclear inflammatory 
cells and absence of an  intraductal component. The term 
‘atypical' medullary carcinoma is used for cases where at least 
one of the features is missing from the diagnostic criteria 
(Table 1) (2). Despite their aggressive histological appearance, 
the prognosis of (atypical) medullary carcinoma appears to be 
more favorable than that of IDC (3,4).
  Another rare form of breast cancer is carcinosarcoma; this 
tumor accounts for less than 1% of all breast cancers (5,6). It 
is a form of metaplastic breast cancer with carcinomatous and 
sarcomatous pathological features. Generally, carcinosarcoma is 
considered an aggressive tumor with a high risk of recurrence. 
Moreover, adjuvant therapy is less effective compared to 
treatment of conventional adenocarcinomas;  therefore, optimal 
treatment for this cancer remains to be defined (7). Atypical 
medullary carcinoma and carcinosarcoma have unique histo-
pathological features.  Here we present a case of malignant 
breast cancer with pathological characteristics of both types of 
cancer.
CASE REPORT
  A 54-year-old postmenopausal woman was admitted with the 
complaint of a right breast mass that was noticed 3 months 
previously. She was taking oral contraceptives for irregular 
vaginal bleeding over the past 2 years. Menarche occurred at 
18 years of age, and her first pregnancy at 26 (Gravida 5 Para 
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Table 1. Histopathologic criteria for classification of medullary carcinoma [modified from Ridolfi et al(2)]
Atypical medullary carcinomaTypical medullary carcinoma (Features of typical medullary carcinoma(All of the following features) but with any of following)
Growth pattern ㆍSyncytial (＞75%) ㆍLess syncytial (＜75%)
Tumor margin infiltration ㆍWell circumscribed ㆍFocal or prominent
Intraductal component ㆍAbsent ㆍPresent
Mononuclear cell infiltration ㆍModerate to marked ㆍMild or negligible 
Nuclear grade ㆍGrade 1 or 2 ㆍGrade 3
Microglandular features ㆍAbsent ㆍPresent
Fig. 1. Initial chest CT findings of the patient. There was an oval necrotic mass measuring 6.0 cm in the greatest dimension in the right 
breast (A) and a small well demarcated lymph node at the right axillary area (B).
2 Live 2 Death 0 Abortion 3); menopause was at the age of 
52. There was no family history of cancer.
  On physical examination, there was a palpable, non-tender 
mass measuring about 5.0 cm in the upper inner quadrant of 
the right breast. There was no discharge or abnormal skin 
retraction around the mass. Axillary and cervical lymph nodes 
were not palpable. The remainder of the examination was 
within normal limits. Mammography showed a high-density 
mass without calcification and an indistinct margin in the right 
breast. Ultrasonography revealed a 5.7 cm-sized mass with 
three right axillary lymph nodes. The core needle biopsy 
showed a poorly differentiated carcinoma. Chest CT revealed 
an oval necrotic mass in the right breast (Fig 1A), and 
non-enlarged lymph nodes (Fig 1B). The clinical stage was 
determined to be cT3N0M0 (Stage IIB) according to the AJCC 
staging system.
  Since the tumor-stage of the patient was advanced and the 
tumor differentiation was very poor, neoadjuvant chemotherapy 
was started immediately. With the impression of locally 
advanced breast cancer, the patient received neoadjuvant 
chemotherapy with a regimen of protracted continuous infusion 
of 5-fluorouracil (1,000 mg/m2) on days 1∼3, combined with 
bolus injections of adriamycin (40 mg/m2) and cyclophos-
phamide (600 mg/m2) on day 1 (infusional FAC regimen), 
which was repeated every three weeks. The patient had grade 
3 neutropenia and grade 1 nausea during chemotherapy. After 
3 cycles of chemotherapy, the breast mass showed stable 
disease (SD) by the RECIST criteria and decreased by 20 
percent (6.0 cm to 4.8 cm). The patient received an additional 
3 cycles of the same regimen. After the sixth cycle, however, 
the tumor size was nearly unchanged (4.6 cm). Due to the 
unsatisfactory tumor shrinkage with this regimen, the chemo-
therapy was then changed to intravenous infusion of paclitaxel 
(175 mg/m2) every three weeks. Even with 3 cycles of 
paclitaxel, regrowth of the breast mass (4.6 cm to 4.9 cm) was 
noted. Predicting that the tumor would no longer be responsive 
to chemotherapy, we performed a modified radical mastectomy.
  The tumor size was 7.0×4.0×4.5 cm without the resection 
margins. Histopathologically, the specimen consisted of a 
poorly differentiated carcinoma with spindle cells (Fig 2A). 
There were frequent multinucleated giant cells noted.  Ten 
axillary lymph nodes were dissected without tumor involve-
ment. The histological grade (HG) of the tumor was III with 
extensive necrosis (Fig 2B, C). The immunohistochemical 
staining was negative for the estrogen receptor (ER), 
progesterone receptor (ER) and c-erbB2, while focally positive 
for vimentin (Fig 2D). The tumor was diagnosed as a 
carcinosarcoma (metaplastic carcinoma) based on poorly differen-
tiated carcinoma cells and sarcomatoid spindle cells. In addi-
tion,  atypical medullary carcinoma was also considered due to 
the features of a well-defined border, a syncytial growth pattern 
without tubular differentiation and highly atypical nuclear 
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Fig. 2. Pathological findings of the surgical specimen. The tumor is well defined and shows multinodular growth of oval and spindle 
tumor cells. There is no evidence of obvious ductal formation or ductal carcinoma in situ. (A, hematoxylin and eosin (H & E) stain, 
×10). Tumor cells form solid sheets with geographic coagulative necrosis (B, H & E stain, ×40). The tumor  cells are pleomorphic and 
very large with brisk mitosis (C, H & E stain, ×400). Immunohistochemical staining for vimentin, the fascicled spindle cells are 
immunoreactive for vimentin (D, DAB, ×200).
features with limited lymphoplasmacytic infiltration. Postopera-
tively, the pathological stage was pT3N0M0 (Stage IIB). The 
patient received postoperative radiotherapy to the tumor site 
with a total dose of 50.4 Gy. At 18 months, the patient is doing 
well without any evidence of recurrence.
DISCUSSION
  Both carcinosarcoma and medullary carcinoma are rare types 
of breast cancer. Carcinosarcoma accounts for less than 1% of 
all breast cancers, and the incidence has been reported to be 
0.8% of all breast malignancies in Korea (5,6).  It is a biphasic 
tumor composed of epithelial and mesenchymal cells. Wargotz 
et al. reported that carcinosarcoma is a distinct form of 
metaplastic carcinoma, describing it as a biphasic neoplasm 
with at least half of the tumor composed of spindle cell 
components and the remaining area consisting of carcinoma (8). 
This tumor is usually negative for hormone receptors and 
c-erbB2 expression. Although the origin of this tumor has not 
been confirmed, some consider it to develop from myoepithelial 
cells (8). Clinically, carcinosarcoma presents as a large, single, 
firm, and rapidly growing mass with infrequent involvement of 
the axillary lymph nodes. However, it is an aggressive tumor 
with a high risk of recurrence and a high mortality rate. The 
recurrence of node-negative carcinosarcoma is around 50∼60% 
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(5,8,9). Surgical treatment, radical mastectomy, is the only 
curative approach. The role of chemotherapy before or after 
surgery has not been established. One study reported that 
patients who were treated with neoadjuvant or adjuvant 
anthracycline-based chemotherapy showed a better clinical out-
come compared to those treated with CMF (cyclophosphamide, 
methotrexate, 5-fluorouracil). However, the neoadjuvant chemo-
therapy for carcinosarcoma was less effective than for conven-
tional adenocarcinoma (7). The prognosis of patients with 
carcinosarcoma is poor with the overall 5-year survival rate less 
than 50% (7∼9). 
  By contrast, medullary carcinoma accounts for 1 to 10 
percent of invasive breast cancers (1). It is a well-circum-
scribed, high-grade tumor with a syncytial growth pattern that 
has aggressive infiltration of mononuclear cells. There is some 
inter-observer variability in the diagnosis of this type of cancer 
(10). The term 'atypical' is added when the medullary tumor 
lacks one of the conventional diagnostic criteria (2). In our 
case, there was limited inflammatory cell infiltration while the 
tumor met the other four diagnostic criteria for medullary 
carcinoma. The prognosis of medullary carcinoma, whether 
'atypical' or typical, is better than that of high grade IDC (11). 
Studies report the overall 10-year survival rate to be 74% and 
more than 90% in a group of node negative patients who 
underwent radical mastectomy (1,2).
  Our patient had a large breast cancer with necrosis, no 
axillary lymph node involvement and poor clinical response to 
neoadjuvant chemotherapy. The tumor had to be surgically 
removed, and its pathological diagnosis was both atypical 
medullary carcinoma and carcinosarcoma. The tumor had all of 
the distinctive features of both of these rare types of breast 
cancer. Staining for vimentin had a minimal contribution to the 
differential diagnosis because both type of cancer can express 
vimentin (8,12). 
  With the findings of negative expression of hormones and 
the c-erbB2 receptor, a so-called triple-negative breast cancer 
was considered in the differential diagnosis. This type of breast 
cancer makes up about 15% of all types of breast cancer, and 
has been morphologically described as metaplastic, atypical or 
typical medullary or adenoid cystic cancers. The pathological 
findings in this case showed a high-grade tumor with increased 
proliferation rate and central necrosis, which are the features 
of a triple-negative cancer. Although the possibility of a 
triple-negative breast cancer still exists for this tumor, we did 
not perform immunoistochemical analysis for CK5/6, EGFR 
and p53 or BRCA1 mutation testing (13). This type of cancer 
is characterized by aggressive behavior and no specific sys-
temic regimen is recommended for its treatment. EGFR  over-
expression or c-KIT expression is often found in triple-negative 
breast cancer and the tyrosine kinase inhibitors for targeting 
these signaling pathways are under clinical investigation (13). 
  The management of a patient with two different pathological 
findings in the same tumor can be a problem, especially when 
the findings have different prognostic implications and require 
different treatments. The prognosis of (atypical) medullary 
carcinoma is favorable without the need for adjuvant therapy. 
However, if carcinosarcoma is taken into consideration, this 
more aggressive tumor requires rigorous follow-up to detect 
recurrence, and additional post-operative therapy would be 
indicated. Since the patient, reported here, showed a minimal 
response to the preoperative chemotherapy with anthracycline 
and taxanes, adjuvant chemotherapy with the same drugs would 
not be expected to confer any additional benefits. Instead, 
radiotherapy to the tumor site was recommended. In one report, 
carcinosarcoma appeared to benefit from sarcoma-type chemo-
therapy containing ifosfamide (7). Other possible agents to 
consider for treatment are gemcitabine, irinotecan and oxali-
platin, which have had no reported proven effect on carcino-
sarcoma of the breast to date.
  In conclusion, atypical medullary carcinoma and carcino-
sarcoma are rare types of breast cancer. Both require surgical 
resection. However, when both are present in the same tumor 
additional treatment should be performed based on the type of 
cancer with the poorer prognosis.
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